The German oncolytic virus therapy market is estimated to grow at a CAGR of more than 14% during the forecast period. Germany is considered as one of the major economies for the global oncolytic virus therapy market. This is largely due to the increasing geriatric population owing to which the risk associated with numerous types of cancers is expected to increase significantly in the near future. Moreover, the presence of highly specialized urologists for cancer treatment and a more feasible cost compared to UK attracting medical tourism in the country, which is also expected to create opportunities for the growth of the market in the near future.
To Request a Sample of our Report on Germany Oncolytic Virus Therapy Market : https://www.omrglobal.com/request-sample/germany-oncolytic-virus-therapy-market-trends
Further, the German oncolytic virus therapy market is segmented on the basis of product and application. Based on the product, the market is segmented into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, Newcastle disease oncolytic viruses, and other oncolytic viruses. HSV-based oncolytic virus therapy held the highest market share of over 94% in 2018, whereas, adenoviruses-based therapy held the rest. Based on the application, the market is segmented into prostate cancer, breast cancer, ovarian cancer, melanoma, and others. In 2018, the melanoma application held the largest market share.
Market Segmentation
Germany Oncolytic Virus Therapy Market by Product
- HSV-Based Oncolytic Virus
- Adenoviruses-Based Oncolytic Virus
- Vaccinia Virus-Based Oncolytic Virus
- Vesicular Stomatitis Virus-Based Oncolytic Virus
- Newcastle Disease Virus- Based Oncolytic Virus
- Others
Germany Oncolytic Virus Therapy Market by Application
- Prostate Cancer
- Breast Cancer
- Ovarian Cancer
- Melanoma
- Other
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
